COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I FLVFLV REGNR2 LY-CoVLY RemdesivirRMD
Vitamin C study #3 of 7
11/3 Pre-Exposure Prophylaxis study (treated before exposed to the virus)
Behera et al., PLOS ONE, doi:10.1371/journal.pone.0247163 (preprint 11/3) (Peer Reviewed)
Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: A matched case-control study
Source   PDF   Share   Tweet
Retrospective matched case-control prophylaxis study for HCQ, ivermectin, and vitamin C with 372 healthcare workers, showing lower COVID-19 incidence for all treatments, with statistical significance reached for ivermectin.
HCQ OR 0.56, p = 0.29
Ivermectin OR 0.27, p < 0.001
Vitamin C OR 0.82, p = 0.58

Behera et al., 11/3/2020, retrospective, India, South Asia, peer-reviewed, 13 authors.
risk of COVID-19 case, 9.6% lower, RR 0.90, p = 0.58, treatment 29 of 67 (43.3%), control 157 of 305 (51.5%), adjusted per study, odds ratio converted to relative risk, model 2 conditional logistic regression.
risk of COVID-19 case, 16.5% lower, RR 0.83, p = 0.04, treatment 29 of 67 (43.3%), control 157 of 305 (51.5%), adjusted per study, odds ratio converted to relative risk, matched pair analysis.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 7 studies
Please send us corrections, updates, or comments.
Submit